Bmf Antibody - BSA Free
Novus Biologicals | Catalog # NBP1-76658
Key Product Details
Validated by
Biological Validation
Species Reactivity
Validated:
Human, Mouse
Cited:
Mouse
Predicted:
Rat (92%). Backed by our 100% Guarantee.
Applications
Validated:
Western Blot, ELISA, Immunocytochemistry/ Immunofluorescence
Cited:
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Format
BSA Free
Loading...
Product Specifications
Immunogen
Antibody was raised with a synthetic peptide corresponding to 15 amino acids near the amino terminus of human Bmf. The immunogen is located within the first 50 amino acids of Bmf. Amino Acid Squence: EPSQCVEELEDDV
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Theoretical MW
22 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for Bmf Antibody - BSA Free
Western Blot: Bmf AntibodyBSA Free [NBP1-76658]
Western Blot: Bmf Antibody [NBP1-76658] - Analysis of Bmf in 293 cell lysate with Bmf antibody at (A) 1 and (B) 2 ug/ml.Western Blot: Bmf Antibody - BSA Free [NBP1-76658] -
Western Blot: Bmf Antibody - BSA Free [NBP1-76658] - Identification of target for LPS-induced miR-29b in OCs. BMMs incubated w/ M-CSF (30 ng/ml) & RANKL (40 ng/ml) for 40 h, washed thoroughly, & incubated further w/ LPS (50 ng/ml) in presence of M-CSF (30 ng/ml) for 48 h. (a) Cells transfected w/ 30 nM of miR-29b mimic or con mimic in presence of M-CSF (30 ng/ml) for 6 h. Total RNA analyzed by qPCR to quantify the expression of BMF, PUMA, BAK1, BIM, & HRK. Expression levels w/ con mimic treatment set at 1. Cell lysates subjected to WB analysis w/ antibodies against BMF, PUMA, BAK1, BIM, HRK, & BCL-2. Antibodies against beta -actin used for normalization. (b) w/out transfection, total RNA analyzed by qPCR to quantify the expression of BMF, & cell lysates subjected to WB analysis w/ anti-BMF Ab. (c) Total RNA & tissue lysate of tibiae from LPS-treated or vehicle-treated (V, PBS) mice analyzed by qPCR to quantify the expression of BMF & subjected to WB analysis w/ antibodies against BMF. (d) Cells thoroughly washed, transfected w/ 30 nM of anti-miR-29b or con inh, & stimulated w/ LPS (50 ng/ml) in presence of M-CSF. After 48 h, total RNA analyzed by qPCR to quantify BMF expression. Expression levels w/ con inh treatment set at 1.0. Cell lysates subjected to WB analysis w/ anti-BMF & anti-BCL-2 Ab. (e) Cells thoroughly washed, transfected w/ 50 nM of scRNA or siBMF, stimulated w/ LPS (50 ng/ml) in presence of M-CSF for 48 h, & analyzed to measure TRAP-positive MNCs & annexin V-positive cells. siRNA-mediated silencing of BMF confirmed by RT-PCR & qPCR. The Ct values of genes widely distributed between 17.33 & 30.92. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001 compared w/ each corresponding control. Similar results obtained from 3 independent experiments. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31093317), licensed under a CC-BY license. Not internally tested by Novus Biologicals.Western Blot: Bmf Antibody - BSA Free [NBP1-76658] -
Western Blot: Bmf Antibody - BSA Free [NBP1-76658] - Identification of target for LPS-induced miR-29b in OCs. BMMs incubated w/ M-CSF (30 ng/ml) & RANKL (40 ng/ml) for 40 h, washed thoroughly, & incubated further w/ LPS (50 ng/ml) in presence of M-CSF (30 ng/ml) for 48 h. (a) Cells transfected w/ 30 nM of miR-29b mimic or con mimic in presence of M-CSF (30 ng/ml) for 6 h. Total RNA analyzed by qPCR to quantify the expression of BMF, PUMA, BAK1, BIM, & HRK. Expression levels w/ con mimic treatment set at 1. Cell lysates subjected to WB analysis w/ antibodies against BMF, PUMA, BAK1, BIM, HRK, & BCL-2. Antibodies against beta -actin used for normalization. (b) w/out transfection, total RNA analyzed by qPCR to quantify the expression of BMF, & cell lysates subjected to WB analysis w/ anti-BMF Ab. (c) Total RNA & tissue lysate of tibiae from LPS-treated or vehicle-treated (V, PBS) mice analyzed by qPCR to quantify the expression of BMF & subjected to WB analysis w/ antibodies against BMF. (d) Cells thoroughly washed, transfected w/ 30 nM of anti-miR-29b or con inh, & stimulated w/ LPS (50 ng/ml) in presence of M-CSF. After 48 h, total RNA analyzed by qPCR to quantify BMF expression. Expression levels w/ con inh treatment set at 1.0. Cell lysates subjected to WB analysis w/ anti-BMF & anti-BCL-2 Ab. (e) Cells thoroughly washed, transfected w/ 50 nM of scRNA or siBMF, stimulated w/ LPS (50 ng/ml) in presence of M-CSF for 48 h, & analyzed to measure TRAP-positive MNCs & annexin V-positive cells. siRNA-mediated silencing of BMF confirmed by RT-PCR & qPCR. The Ct values of genes widely distributed between 17.33 & 30.92. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001 compared w/ each corresponding control. Similar results obtained from 3 independent experiments. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31093317), licensed under a CC-BY license. Not internally tested by Novus Biologicals.Western Blot: Bmf Antibody - BSA Free [NBP1-76658] -
Western Blot: Bmf Antibody - BSA Free [NBP1-76658] - Identification of target for LPS-induced miR-29b in OCs. BMMs incubated w/ M-CSF (30 ng/ml) & RANKL (40 ng/ml) for 40 h, washed thoroughly, & incubated further w/ LPS (50 ng/ml) in presence of M-CSF (30 ng/ml) for 48 h. (a) Cells transfected w/ 30 nM of miR-29b mimic or con mimic in presence of M-CSF (30 ng/ml) for 6 h. Total RNA analyzed by qPCR to quantify the expression of BMF, PUMA, BAK1, BIM, & HRK. Expression levels w/ con mimic treatment set at 1. Cell lysates subjected to WB analysis w/ antibodies against BMF, PUMA, BAK1, BIM, HRK, & BCL-2. Antibodies against beta -actin used for normalization. (b) w/out transfection, total RNA analyzed by qPCR to quantify the expression of BMF, & cell lysates subjected to WB analysis w/ anti-BMF Ab. (c) Total RNA & tissue lysate of tibiae from LPS-treated or vehicle-treated (V, PBS) mice analyzed by qPCR to quantify the expression of BMF & subjected to WB analysis w/ antibodies against BMF. (d) Cells thoroughly washed, transfected w/ 30 nM of anti-miR-29b or con inh, & stimulated w/ LPS (50 ng/ml) in presence of M-CSF. After 48 h, total RNA analyzed by qPCR to quantify BMF expression. Expression levels w/ con inh treatment set at 1.0. Cell lysates subjected to WB analysis w/ anti-BMF & anti-BCL-2 Ab. (e) Cells thoroughly washed, transfected w/ 50 nM of scRNA or siBMF, stimulated w/ LPS (50 ng/ml) in presence of M-CSF for 48 h, & analyzed to measure TRAP-positive MNCs & annexin V-positive cells. siRNA-mediated silencing of BMF confirmed by RT-PCR & qPCR. The Ct values of genes widely distributed between 17.33 & 30.92. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001 compared w/ each corresponding control. Similar results obtained from 3 independent experiments. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31093317), licensed under a CC-BY license. Not internally tested by Novus Biologicals.Immunocytochemistry/ Immunofluorescence: Bmf Antibody - BSA Free [NBP1-76658] -
Immunocytochemistry/ Immunofluorescence: Bmf Antibody - BSA Free [NBP1-76658] - Immunofluorescence of Bmf in HeLa cells with Bmf antibody at 5 ug/mL.Red: Bmf Antibody
Blue: DAPI staining
Immunocytochemistry/ Immunofluorescence: Bmf Antibody - BSA Free [NBP1-76658] -
Immunocytochemistry/ Immunofluorescence: Bmf Antibody - BSA Free [NBP1-76658] - Immunocytochemistry of Bmf in HeLa cells with Bmf antibody at 10 ug/mL.Applications for Bmf Antibody - BSA Free
Application
Recommended Usage
ELISA
1:100-1:2000
Immunocytochemistry/ Immunofluorescence
5-10 ug/ml
Western Blot
1-2 ug/ml
Formulation, Preparation, and Storage
Purification
Peptide affinity purified
Formulation
PBS
Format
BSA Free
Preservative
0.02% Sodium Azide
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: BMF
Long Name
Bcl-2 Modifying Factor
Alternate Names
Bcl2 modifying factor, bcl-2-modifying factor, FLJ00065
Gene Symbol
BMF
UniProt
Additional BMF Products
Product Documents for Bmf Antibody - BSA Free
Certificate of Analysis
To download a Certificate of Analysis, please enter a lot or batch number in the search box below.
Product Specific Notices for Bmf Antibody - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Related Research Areas
Citations for Bmf Antibody - BSA Free
Customer Reviews for Bmf Antibody - BSA Free
There are currently no reviews for this product. Be the first to review Bmf Antibody - BSA Free and earn rewards!
Have you used Bmf Antibody - BSA Free?
Submit a review and receive an Amazon gift card!
$25/€18/£15/$25CAN/¥2500 Yen for a review with an image
$10/€7/£6/$10CAN/¥1110 Yen for a review without an image
Submit a review
Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
- Appropriate Fixation of IHC/ICC Samples
- Cellular Response to Hypoxia Protocols
- ClariTSA™ Fluorophore Kits
- Detection & Visualization of Antibody Binding
- ELISA Sample Preparation & Collection Guide
- ELISA Troubleshooting Guide
- How to Run an R&D Systems DuoSet ELISA
- How to Run an R&D Systems Quantikine ELISA
- How to Run an R&D Systems Quantikine™ QuicKit™ ELISA
- ICC Cell Smear Protocol for Suspension Cells
- ICC Immunocytochemistry Protocol Videos
- ICC for Adherent Cells
- Immunocytochemistry (ICC) Protocol
- Immunocytochemistry Troubleshooting
- Immunofluorescence of Organoids Embedded in Cultrex Basement Membrane Extract
- Immunohistochemistry (IHC) and Immunocytochemistry (ICC) Protocols
- Preparing Samples for IHC/ICC Experiments
- Preventing Non-Specific Staining (Non-Specific Binding)
- Primary Antibody Selection & Optimization
- Protocol for VisUCyte™ HRP Polymer Detection Reagent
- Protocol for the Fluorescent ICC Staining of Cell Smears - Graphic
- Protocol for the Fluorescent ICC Staining of Cultured Cells on Coverslips - Graphic
- Protocol for the Preparation and Fluorescent ICC Staining of Cells on Coverslips
- Protocol for the Preparation and Fluorescent ICC Staining of Non-adherent Cells
- Protocol for the Preparation and Fluorescent ICC Staining of Stem Cells on Coverslips
- Protocol for the Preparation of a Cell Smear for Non-adherent Cell ICC - Graphic
- Quantikine HS ELISA Kit Assay Principle, Alkaline Phosphatase
- Quantikine HS ELISA Kit Principle, Streptavidin-HRP Polymer
- R&D Systems Quality Control Western Blot Protocol
- Sandwich ELISA (Colorimetric) – Biotin/Streptavidin Detection Protocol
- Sandwich ELISA (Colorimetric) – Direct Detection Protocol
- TUNEL and Active Caspase-3 Detection by IHC/ICC Protocol
- The Importance of IHC/ICC Controls
- Troubleshooting Guide: ELISA
- Troubleshooting Guide: Western Blot Figures
- Western Blot Conditions
- Western Blot Protocol
- Western Blot Protocol for Cell Lysates
- Western Blot Troubleshooting
- Western Blot Troubleshooting Guide
- View all Protocols, Troubleshooting, Illustrated assays and Webinars
Loading...